Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
← catalyst calendarNCT07223593 · readout ≤ 681 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
1,205estimated
Sites
157
Countries
Argentina, Australia, Brazil +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-31 | actual | When the study began enrolling |
| Primary completion | Jun 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Peripheral Arterial Disease
Interventions
- Drug: Orforglipron — also filed as LY3502970
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent Change from Baseline in Maximum Walking Distance
measured Baseline, Week 52
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed